Abstract
Clopidogrel (a widely used second-generation thienopyridine) therapy is associated with an unpredictable pharmacodynamic response whereby approximately 1 in 3 patients will have a high on-treatment platelet reactivity to adenosine diphosphate. High on-treatment platelet reactivity is an established risk factor for ischemic event occurrence in patients undergoing percutaneous coronary intervention. Platelet function testing may have a role in monitoring therapeutic efficacy when clopidogrel is the chosen agent and in safety when more potent drugs are used, especially in patients with high bleeding risk. At this time, it seems most reasonable to assess platelet function in high-risk clopidogrel-treated patients.
Original language | English (US) |
---|---|
Pages (from-to) | 607-614 |
Number of pages | 8 |
Journal | Interventional Cardiology Clinics |
Volume | 2 |
Issue number | 4 |
DOIs | |
State | Published - Oct 2013 |
Keywords
- Bleeding
- Clopidogrel
- High on-treatment platelet reactivity
- P2Y receptor
- Percutaneous coronary intervention
- Platelet function testing
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine